title: Hydroxyurea inhibition of cellular and developmental activities in the decidualized and pregnant uteri of rats.
abstract: The cytotoxicity of hydroxyurea (HU), currently used to combat various cancers, sickle cell anemia and human immunodeficiency infection, was assessed by exposing decidualized and pregnant uteri of Sprague-Dawley rats to this drug. Consecutive daily doses of HU (500 mg/kg(-1)) for 4 days were injected subcutaneously during decidualization when proliferation of the deciduoma was biochemically analyzed on pseudopregnancy day 9, or injected intraperitoneally during pregnancy when uterine developmental processes were evaluated on gestation day 16. Hydroxyurea displayed prominent antiproliferative effects on decidual growth. These actions were comparable to significantly impaired (P<0.001) developmental responses (increases in post-implantation losses, in resorbed fetuses and in reduced fetal and placental weights) during pregnancy. The cellular components inhibited by HU were DNA, protein, nitric oxide synthase, a matrix metalloproteinase and decidual prolactin-related protein mRNA (P<0.05). Steroid-related endocrine events (serum progesterone concentrations, estrogen receptor and mRNA levels) were unaffected by HU, implying direct cellular action by the drug. Interestingly, endometrial alkaline phosphatase bioactivity was enhanced by HU (P<0.05). Subsequently, the reproductive toxicity of HU was apparently related to mitogenic and differentiation-induced endometrial cellular activities.
authors.affiliation: Health Research Center, Biology Department, Southern University, Baton Rouge, LA 70813, USA.
authors.forename: F
authors.initials: F
authors.lastname: Spencer
authors.forename: L
authors.initials: L
authors.lastname: Chi
authors.forename: M X
authors.initials: MX
authors.lastname: Zhu
mesh_terms: D000818:Animals; D015153:Blotting, Western; D003656:Decidua / Q000166:cytology* / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006918:Hydroxyurea / Q000494:pharmacology*; D020782:Matrix Metalloproteinases / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000378:metabolism; D011247:Pregnancy; D011555:Pseudopregnancy / Q000201:enzymology; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D011960:Receptors, Estrogen / Q000187:drug effects; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*; D014599:Uterus / Q000166:cytology / Q000187:drug effects / Q000254:growth & development*
chemical_list: D004791:Enzyme Inhibitors; D012333:RNA, Messenger; D011960:Receptors, Estrogen; D019001:Nitric Oxide Synthase; D012264:Ribonucleotide Reductases; D020782:Matrix Metalloproteinases; D006918:Hydroxyurea